AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial
Updated
Updated · Yahoo Finance · Aug 10
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial
3 articles · Updated · Yahoo Finance · Aug 10
Summary
ABCL-635 cut moderate-to-severe hot flashes by 83% from baseline after four weeks, versus 33% for placebo, in a 92-patient Phase II study of post-menopausal women.
The treatment group saw 8.8 fewer events per day against 3.5 for placebo, a placebo-adjusted reduction of 5.3 daily events; the benefit was already statistically significant by week one.
Severity also improved: mean scores fell 1.4 points with ABCL-635 versus 0.3 with placebo, bringing treated patients down to a mild-event range while placebo patients remained in the moderate range.
No serious or severe adverse events were reported in the ABCL-635 arm; AbCellera said headaches, fatigue and one mild resolved liver-enzyme elevation were observed.
AbCellera is now prioritizing ABCL-635, collecting 12-week follow-up data to gauge dosing frequency and weighing Phase III paths, including a possible head-to-head trial.